{"id":"csii-followed-by-lina","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination therapy uses an insulin pump (CSII) to deliver continuous background insulin with meal-time boluses, while liraglutide enhances insulin secretion, slows gastric emptying, and promotes satiety through GLP-1 receptor activation. The sequential or concurrent use aims to optimize blood glucose management while potentially reducing insulin requirements and supporting weight loss.","oneSentence":"CSII (continuous subcutaneous insulin infusion) followed by liraglutide (Lina) provides basal-bolus insulin delivery combined with GLP-1 receptor agonism to improve glycemic control in diabetes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:29:27.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus requiring intensive glycemic control"}]},"trialDetails":[{"nctId":"NCT03194945","phase":"PHASE4","title":"Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-11-01","conditions":"Type 2 Diabetes Mellitus","enrollment":412}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CSII+Lina"],"phase":"marketed","status":"active","brandName":"CSII followed by Lina","genericName":"CSII followed by Lina","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CSII (continuous subcutaneous insulin infusion) followed by liraglutide (Lina) provides basal-bolus insulin delivery combined with GLP-1 receptor agonism to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus requiring intensive glycemic control.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}